Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback